ロード中...
Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
Palbociclib is a highly selective, reversible, oral inhibitor of cyclin‐dependent kinases 4 and 6 that is approved to treat hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer. An open‐label, single‐arm, Japanese phase 2 study was conducted to investiga...
保存先:
| 出版年: | Cancer Med |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7367628/ https://ncbi.nlm.nih.gov/pubmed/32420697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3091 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|